Abstract
Many patients with hemophilia, particularly those with inhibitory antibodies, utilize central venous access devices (CVADs) to facilitate frequent infusions. Infection of these devices is a common complication of factor replacement therapy. This communication reports our center's experience with CVAD infection in three patients with severe hemophilia A undergoing immune tolerance therapy (ITT) in whom intermittent infusions of recombinant tissue plasminogen activator (rTPA, Cathflo™ Activase®) were utilized. In this small experience, patients experienced a decreased frequency of gram-positive infections when receiving routine rTPA treatments. Larger randomized trial should be performed in this patient population at high risk of CVAD infection.
| Original language | English |
|---|---|
| Pages (from-to) | 627-629 |
| Number of pages | 3 |
| Journal | Pediatric Blood and Cancer |
| Volume | 50 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2008 |
Keywords
- Central venous access device
- Hemophilia
- Infection
- Tissue plasminogen activator
Fingerprint
Dive into the research topics of 'Recombinant tissue plasminogen activator may reduce frequency of central venous access device infection in hemophilia patients undergoing immune tolerance therapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver